By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A US Food and Drug Administration panel will not review Gen-Probe's submission for clearance of its Progensa PCA3 assay for prostate cancer in October as previously scheduled, the San Diego-based company disclosed in a regulatory filing after the close of the market Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.